BRIEF-Disc Medicine Announces Successful End Of Phase 2 Meeting With FDA For Bitopertin In Erythropoietic Protoporphyria

Reuters
2024-11-04

Nov 4 (Reuters) - Disc Medicine Inc :

* DISC MEDICINE ANNOUNCES SUCCESSFUL END OF PHASE 2 MEETING WITH FDA FOR BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA $(EPP.UK)$, INCLUDING POTENTIAL FOR ACCELERATED APPROVAL

* DISC MEDICINE INC - TO INITIATE APOLLO TRIAL BY MID-2025

* DISC MEDICINE INC - FDA AGREES WITH ALL PROPOSED STUDY PARAMETERS FOR BITOPERTIN

Source text: Further company coverage:

(Reuters.Briefs@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10